QuickView for Fenofibrate (compound)

Summary
General Info

PubChem

PubChem Compound 3339

Name:	Fenofibrate
PubChem Compound ID:	3339
Description:	An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
Molecular formula:	C₂₀H₂₁ClO₄
Molecular weight:	360.831 g/mol
Synonyms:	Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate; Antara; KBioGR_000706; Lipoclar; KBio1_000557; Triglide; Lipidil; Elasterin; Lopac-F-6020; Prestwick_217. show more » Isopropyl 2-(p-(p-chlorobenzoyl)phenoxy)-2-methylpropionate; Antara; KBioGR_000706; Lipoclar; KBio1_000557; Triglide; Lipidil; Elasterin; Lopac-F-6020; Prestwick_217; NSC 281319; Lipifen; nchembio790-comp24; AIDS-165956; SMR000058299; Sedufen; Fenobrate; Lipofene; Fenofibratum [INN-Latin]; propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate; NCGC00015437-02; Prestwick1_000275; NCGC00015437-01; EU-0100486; 49562-28-9; SPBio_001380; Lipsin; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-, 1-methylethyl ester; Spectrum_001250; AIDS165956; KBio2_006866; D00565; Lipantil (TN); NSC281319; KBio2_001730; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid 1-methylethyl ester; Tricor (TN); C07586; Luxacor; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid 1-methylethyl ester; KBioSS_001730; Lipantil; Finofibrate; CHEBI:5001; SPBio_002369; Fenotard; Spectrum3_001431; Spectrum4_000413; Tricor; Elasterate; Fenofibrato [INN-Spanish]; Lipanthyl; Protolipan; Fenofibrate (JAN); Isopropyl (4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate; Spectrum2_001390; KBio2_004298; Isopropyl 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate; Secalip; DivK1c_000557; MLS000028515; Fenofibrate [BAN:INN]; LF-178; Lipidex; Prestwick0_000275; Liposit; LS-121256; Procetofen; Lipirex; Fenofibrate; Proctofene; Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester; BRN 2062462; KBio3_002382; Nolipax; CAS-49562-28-9; Ankebin; Fenogal; NINDS_000557; CCRIS 7282; EINECS 256-376-3; FNF show less «

DrugBank

Identification

Name:	Fenofibrate
Name (isomeric):	DB01039
Drug Type:	small molecule
Description:	An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
Synonyms:	Fenofibratum [INN-Latin]; Fenofibrato [INN-Spanish]; Fenofibric acid; Finofibrate; FNF
Brand:	Lipantil, Tricor, Lipanthyl, Lipifen, Liposit, Lipidex, Antara, Lipsin, Lipoclar, Elasterate, Lipofene, Fenobrate, Elasterin, Lipirex, Trilipix, Triglide, Sedufen, Fenotard, Protolipan, Secalip, Lipidil Supra, Procetofen, Nolipax, Proctofene, Fenogal, Lofibra, Lipidil Micro, Lipidil, Ankebin, Luxacor
Category:	Fribic Acid Derivatives, Antilipemic Agents
CAS number:	49562-28-9

Pharmacology

Indication:	For use as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb)
Pharmacology:	Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult... show more » Fenofibrate is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with fenofibrate results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII. show less «
Mechanism of Action:	Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the siz... show more » Fenofibrate exerts its therapeutic effects through activation of peroxisome proliferator activated receptor a (PPARa). This increases lipolysis and elimination of triglyceride-rich particles from plasma by activating lipoprotein lipase and reducing production of apoprotein C-III. The resulting fall in triglycerides produces an alteration in the size and composition of LDL from small, dense particles, to large buoyant particles. These larger particles have a greater affinity for cholesterol receptors and are catabolized rapidly. show less «
Absorption:	Fenofibrate is well absorbed from the gastrointestinal tract. After absorption, fenofibrate is mainly excreted in the urine in the form of metabolites, primarily fenofibric acid and fenofibric acid glucuronide
Protein binding:	~99% (Serum protein binding)
Route of elimination:	Fenofibric acid is primarily conjugated with glucuronic acid and then excreted in urine. Following oral administration in healthy volunteers, approximately 60% of a single dose of radiolabelled fenofibrate appeared in urine, primarily as fenofibric acid and its glucuronate conjugate and 25% was excreted in the feces.
Half Life:	20 hours
Clearance:	1.2 L/h [Eldery]
Toxicity:	LD₅₀=1600 mg/kg (Oral, in mice); Investigated as a teratogen and reproductive hazard.
Affected organisms:	Humans and other mammals

Interactions

Food interaction:

Increased absorption- take with meals.

Drug interaction:

Pravastatin	Increased risk of myopathy/rhabdomyolysis
Dicumarol	Fenofibrate may increase the anticoagulant effect of dicumarol.
Anisindione	Fenofibrate may increase the anticoagulant effect of anisindione.
Ursodeoxycholic acid	The fibric acid derivative decreases the effect of ursodiol
Rosuvastatin	May cause additive myotoxicity. Monitor for symptoms of muscle toxicity during concomitant therapy.

Targets

Peroxisome proliferator-activated receptor alpha

Receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids

UniProt ID:

Q07869

Gene:

PPARA

Actions:

agonist

References:

Clavey V, Copin C, Mariotte MC, Bauge E, Chinetti G, Fruchart J, Fruchart JC, Dallongeville J, Staels B: Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells. Cell Physiol Biochem. 1999;9(3):139-49.
View Article

Chaput E, Saladin R, Silvestre M, Edgar AD: Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight. Biochem Biophys Res Commun. 2000 May 10;271(2):445-50.
View Article

Casas F, Pineau T, Rochard P, Rodier A, Daury L, Dauca M, Cabello G, Wrutniak-Cabello C: New molecular aspects of regulation of mitochondrial activity by fenofibrate and fasting. FEBS Lett. 2000 Sep 29;482(1-2):71-4.
View Article

Bouly M, Masson D, Gross B, Jiang XC, Fievet C, Castro G, Tall AR, Fruchart JC, Staels B, Lagrost L, Luc G: Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate. J Biol Chem. 2001 Jul 13;276(28):25841-7. Epub 2001 May 7.
View Article

Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr: Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat. Metabolism. 2001 Aug;50(8):963-71.
View Article

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
View Article

Guerre-Millo M, Gervois P, Raspe E, Madsen L, Poulain P, Derudas B, Herbert JM, Winegar DA, Willson TM, Fruchart JC, Berge RK, Staels B: Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
View Article

Enzymes